Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1750
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients ; volume:197 ; number:5 ; day:22 ; month:8 ; year:2019 ; pages:551-558 ; date:10.2019
Lung ; 197, Heft 5 (22.8.2019), 551-558, 10.2019
- Urheber
-
Proesmans, V. L. J.
Drent, M.
Elfferich, M. D. P.
Wijnen, P. A. H. M.
Jessurun, N. T.
Bast, A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00408-019-00260-1
- URN
-
urn:nbn:de:101:1-2020021309332968509035
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Proesmans, V. L. J.
- Drent, M.
- Elfferich, M. D. P.
- Wijnen, P. A. H. M.
- Jessurun, N. T.
- Bast, A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Antifibrotic Therapies in the Liver
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
Antifibrotic therapies to control cardiac fibrosis
Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Antifibrotic Therapies in the Liver
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
Antifibrotic therapies to control cardiac fibrosis
Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Antifibrotic Therapies in the Liver
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
Antifibrotic therapies to control cardiac fibrosis
Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis